Mutant FGF-21 peptide pegylated conjugates and uses thereof
US10407479B2 · kind B2 · utility
7Cited by
5References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 19, 2018 |
| Grant date | Sep 10, 2019 |
| Priority date | — |
| Expiry date | Dec 19, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate comprising a PEG moiety attached to a mutant FGF-21 peptide via a glycosyl linker and uses thereof. Further provided is a method for producing the mutant FGF-21 peptide conjugate and a pharmaceutical composition and container comprising said mutant FGF-21 peptide conjugate.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.